Biotech Firm Revolutionizing Amino-Acid Manufacturing Closes $12 Million Series A Financing Round
SAN LEANDRO, CA — Aralez Bio, a platform technology company with a proprietary enzymatic approach for designing and manufacturing noncanonical amino acids (ncAAs), announced the close of its oversubscribed $12 million Series A financing today. The round was led by Spero Ventures with matched investment from Paladin Capital Group. Additional investors included Good Growth Capital, Astia […]
Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, and New Partnership with Alloy Therapeutics
Financing will fund growth and expansion of new functional single-cell analysis and sorting product lines for drug discovery, enabled by Partillion’s proprietary Nanovial technology. Partillion Bioscience Corporation (“Partillion”), a life science tools company, today announced the closing of a $5 million seed financing round, expansion of its board of directors, and a multiyear agreement with Alloy Therapeutics, […]
Mérieux Développement and Paladin Capital Group co-lead $55.5 million Series C financing into Inscripta, a leading company in the field of gene editing, in preparation for platform expansion and commercial launch.
Investment will accelerate development and commercialization of gene-editing tools including enzymes, reagents, instrumentation, and software San Francisco, Lyon and Boston, February 28, 2018 – Merieux Developpement and Paladin Capital Group announced the completion of a $55.5 million Series C funding into Inscripta, a leading gene-editing technology company, based in Boulder, CO and Pleasanton, CA. Additional […]